EREric Richard

Eric Richard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Richard has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The backbone model of the Arabis mosaic virus reveals new insights into functional domains of Nepovirus capsid

    by Joséphine Lai-Kee-Him, Pascale Schellenberger, Christian Dumas, Eric Richard, Stefano Trapani, Véronique Komar, Gerard Demangeat, Christophe Ritzenthaler, Patrick Bron


  • Open Access

    The Opening of the SPP1 Bacteriophage Tail, a Prevalent Mechanism in Gram-positive-infecting Siphophages

    by Adeline Goulet, Joséphine Lai-Kee-Him, David Veesler, Isabelle Auzat, Gautier Robin, Dale A. Shepherd, Alison E. Ashcroft, Eric Richard, Julie Lichière, Paulo Tavares, et al.


  • Open Access

    FATP1 Inhibits 11-cis Retinol Formation via Interaction with the Visual Cycle Retinoid Isomerase RPE65 and Lecithin:Retinol Acyltransferase

    by Thomas J.P. Guignard, Minghao Jin, Marie O. Pequignot, Songhua Li, Yolaine Chassigneux, Karim Chekroud, Laurent Guillou, Eric Richard, Christian P. Hamel, Philippe Brabet


  • Crosslinking Photosensitized by a Ruthenium Chelate as a Tool for Labeling and Topographical Studies of G-Protein-Coupled Receptors

    by Isabelle Duroux-Richard, Philippe Vassault, Guy Subra, Jean-François Guichou, Eric Richard, Bernard Mouillac, Claude Barberis, Jacky Marie, Jean-Claude Bonnafous


  • Identification by MALDI-TOF Mass Spectrometry of 17α-Bromoacetamidopropylestradiol Covalent Attachment Sites on Estrogen Receptor α

    by Hélène Mattras, Sigrid Aliau, Eric Richard, Jean-Claude Bonnafous, Patrick Jouin, Jean-Louis Borgna

    Mass spectrometry was used to identify the sites of covalent attachment of [14C]-17α-bromoacetamidopropylestradiol ([14C]17BAPE2, an estradiol agonist) to the ligand-binding domain (LBD) of mouse estrogen receptor α (ERα). A glutathione S-transferase (GST)−LBD chimera protein was overexpressed in Escherichia coli, using a vector encoding GST fused with a C-terminal portion of mouse ERα (Ser313−Ile599), via a sequence enclosing a thrombin cleavage site (located 14 amino acids ahead of Ser313). [14C]17BAPE2 covalent labeling experiments were carried out on the GST−LBD chimera immobilized on glutathione−Sepharose. After thrombin cleavage of the chimeric LBD, two major [14C]17BAPE2-labeled species of 34 (∼75%) and 30 kDa (∼25%) were detected by SDS−PAGE and autoradiography. Their identity was assessed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS): two main signals were consistent with the mass of the full-length (Ser313−Ile599) and truncated LBD (Ser313−Ala573), both comprising the extra 14 N-terminal amino acids and covalently bound [14C]17BAPE2 (via HBr elimination). A purified 14C-labeled LBD preparation was trypsinized to identify the covalent attachment sites of 17BAPE2. HPLC of tryptic fragments only revealed two discrete and practically equivalent radioactive fractions. MALDI-TOF MS analysis of these two fractions showed only two signals which exactly matched the molecular masses of the [14C]17BAPE2-alkylated Cys534Lys535 and Cys421−Arg438 peptides, respectively. Hydrolysis of the second 14C-labeled fraction by Staphylococcus aureus V8 Glu-C endoproteinase generated signals typical of alkylated the Cys421−Glu423 tripeptide. We concluded that Cys421 and Cys534 were equivalent alternative covalent attachment sites of 17BAPE2 on the LBD. These biochemical data were interpreted using the crystallographic structures of estradiol−LBD and raloxifene− or 4-hydroxytamoxifen−LBD complexes. The covalent attachment to Cys421, Cys534, or both could be interpreted according to the starting structure. Various hypotheses based on the biochemical results and molecular modeling simulations are discussed, with the likely involvement of dynamic interconversion between multiple conformational states of the LBD−17BAPE2 complex.


  • Differential Interactions of Estrogens and Antiestrogens at the 17β-Hydroxyl or Counterpart Hydroxyl with Histidine 524 of the Human Estrogen Receptor α

    by Sigrid Aliau, Hélène Mattras, Eric Richard, Jean-Claude Bonnafous, Jean-Louis Borgna

    We investigated the role of H524 of the human estrogen receptor α (ERα) for the binding of various estrogens [estradiol (E2), 3-deoxyestradiol (3-dE2), and 17β-deoxyestradiol (17β-dE2)] and antiestrogens [4-hydroxytamoxifen (OHT), RU 39 411 (RU), and raloxifene (Ral)], which possess the 17β-hydroxyl or counterpart hydroxyl (designated: 17β/c-OH), with the exception of 17β-dE2 and OHT. The work involved a comparison of the binding affinities of these ligands for wild-type and H524 mutant ERs, modified or not with diethyl pyrocarbonate (DEPC), a selective histidine reagent. Alanine substitution of H524 did not significantly change the association affinity constant (relative to OHT) of 17β-dE2, whereas those of RU, Ral, E2, and 3-dE2 were decreased 3-fold, 14-fold, 24-fold, and 49-fold, respectively. Values of the two ligands available in radiolabeled form (E2 and OHT) were correlated with the dissociation rate constants, which were increased 250-fold and 2-fold, respectively. The action of DEPC on wild-type ER led to a homogeneous ER population which still bound antiestrogens and 17β-dE2 with practically unchanged affinities (less than 4-fold decreases in relative affinity constants), while E2 and 3-dE2 displayed markedly decreased affinities (56-fold decrease for E2). Conversely, DEPC treatment of H524A mutant ER did not induce marked decreases in the relative affinities of any of the checked compounds (decreases ≤3-fold). All of these effects appeared to involve H524 as the H516A mutant behaved as wild-type ER. These combined data relative to mutated or DEPC-modified ER converged to support that the interaction of 17β/c-OH of ER ligands with H524 is strong for estrogens and weaker for antiestrogens, with quantitative or qualitative differences between the binding modes of the latter, as illustrated by RU and Ral. The abilities of E2 and OHT to protect the various ER types against inactivation by DEPC were strikingly different: OHT totally prevented the effect of DEPC on wild-type, H516A, and H524A ERs, while E2 only partially protected wild-type and H516A ERs (H516A ER > wild-type ER) and very weakly protected H524A ER. Molecular modeling was tentatively used to interpret the biochemical results.


  • Open Access

    Control of Conformational Equilibria in the Human B2 Bradykinin Receptor

    by Jacky Marie, Eric Richard, Didier Pruneau, Jean-Luc Paquet, Christian Siatka, Renée Larguier, Cecilia Poncé, Philippe Vassault, Thierry Groblewski, Bernard Maigret, et al.


  • Cysteine 530 of the Human Estrogen Receptor α Is the Main Covalent Attachment Site of 11β-(Aziridinylalkoxyphenyl)estradiols

    by Sigrid Aliau, Hélène Mattras, Eric Richard, Jean-Louis Borgna

    The efficiency of 11β-[p(aziridinylethoxy)phenyl]estradiol 1 and 11β-[p(aziridinylpentoxy)phenyl]estradiol 2 affinity labeling of the estrogen receptor α (ERα) was evaluated on the basis of their capacity to inhibit [3H]estradiol binding to lamb and human ERαs. Relative to RU 39 411 (11β-[p(dimethylaminoethoxy)phenyl]estradiol), the most closely related and chemically inert analogue of 1, the two electrophiles irreversibly inhibited [3H]estradiol binding to the lamb ERα. The fact that the compound effects were prevented (i) when the ERα hormone-binding site was occupied by estradiol and (ii) when the ERα-containing extracts were pretreated with methyl methanethiosulfonate (an SH-specific reagent) suggested that the compounds specifically alkylated ERα at cysteine residues. Wild-type human ERα was alkylated as efficiently as lamb ER, whereas the quadruple cysteine → alanine mutant, in which all cysteines of the hormone-binding domain (residues 381, 417, 447, and 530) were changed to alanines, showed no significant electrophile labeling. The single C530A mutant was much less sensitive to the action of the electrophiles than the three other single mutants (C381A, C417A, and C447A). Moreover, analysis of the three double mutants (C381A/C530A, C417A/C530A, and C447A/C530A) showed that only the C381A/C530A mutant was less susceptible to electrophile labeling than the single C530A mutant. We concluded that in the hormone-binding pocket C530 was the main covalent attachment site of aziridines 1 and 2, whereas C381 could be a secondary site. These results agreed with the crystal structure of the hormone-binding domain of the human ERα bound to estrogen or antiestrogen, since C381 and C530 appeared to be (i) located in structural elements involved in delineating the hormone-binding pocket and (ii) in spatial proximity to each other, which was closer in the crystal structure of the ER:antiestrogen complex than in that of the ER:estrogen complex. Since C530 and C381 were also the main and secondary covalent attachment sites of tamoxifen aziridine (a nonsteroidal affinity-labeling agent), we propose a selective mode of superimposition of tamoxifen-class antiestrogens with RU 39 411-class antiestrogens, which could account for the relative positioning of the two types of ligands in the ERα hormone-binding pocket.